Malik's Bold Move: 1789 Capital Invests in Controversial Drug Startup BlinkRx

In a striking development within the pharmaceutical investment landscape, 1789 Capital, under the leadership of co-founder and activist investor Vivek Malik, has announced a significant investment in BlinkRx, a drug startup that is rapidly making waves for its unique business model and strong ideological stance. This partnership is not just about financial backing; it also exemplifies Malik's commitment to moving against the prevailing “woke” culture that he believes has stifled innovation and growth in the industry.

Continue reading